

**Table S1. Surface marker expression in BM MSCs, SVCs, ASCs, committed preadipocytes and mature adipocytes.**

	Marker		BM MSCs	MSCs (ISCT criteria)	SVCs (unsorted)	ASCs	Committed Preadipocytes	Adipocytes	Marker expression pattern
	Common name	Gene name or description							
	CD166	ALCAM	(72, 172)		(103)	(21, 86, 103, 152, 172, 245)			Different between SVCs and ASCs
	CD45	PTPRC; protein tyrosine phosphatase, receptor type C	(72, 81, 111, 119, 159, 172, 252)	(116)	(47, 49, 109, 158)	(21, 47, 81, 86, 96, 98, 109, 111, 120, 130, 145, 152, 170, 172, 245)	(24, 189)		
	vWF	von Willebrand factor	(72)		(105)	(47, 103, 121)			
Enriched in adipogenic ASCs or committed preadipocytes	Lin	CD2, CD3, CD4, CD5, CD6, NK1.1, B220, Ter-119 and Gr-			(158, 189)	(98)	(189)		Different between SVCs and ASCs (but some inconsistent reports)
	CD31	PECAM-1	(72, 81, 111, 119, 172, 252)		(22, 47, 49, 103, 106, 107, 124, 161) (109)	(103) (172) (21, 22, 47, 81, 86, 98, 109, 111, 120, 121, 124, 245)	(161, 189)	(106, 161)	
	CD34	CD34; Stem cell marker; CD62L receptor	(72, 81, 119, 159, 172, 252)	(116)	(22, 47, 49, 97, 103, 104, 106, 107, 109, 118, 124, 158, 159, 161, 163, 189)	(22, 86, 103, 109, 118, 124, 163, 172, 189, 245) (47, 81, 91, 98, 120, 121, 130, 145, 147, 152, 170, 244)	(24, 161, 189)	(106, 161)	
	CD117	c-kit; SCFR	(172, 252)		(163) (108)	(105) (172) (98, 147, 170)	(189)		
	CD11a	Integrin αL; LFA-1	(72)		(47) (108)	(86)			
	CD14	LPS-R	(72, 119, 159, 172)	(116)	(47, 161) (106, 109, 244)	(21, 81, 86, 109) (172)	(161)	(106, 161)	
	CD15	LewisX; SSEA-1	(72)		(106)	(147) (23)		(106)	
	CD73	NT5E; SH3	(72, 81, 111, 119, 172)	(116)	(103, 159, 244)	(81, 103, 111, 130, 145, 170, 172) (105)			
	CD133	AC133			(98) (108)	(105, 147, 170)			
	CD144	VE-cadherin			(22, 109) (103)	(22, 103, 109, 120, 121, 170)			
	CD146	MCAM (melanoma cell adhesion molecule)			(103, 124)	(21, 86, 121) (120, 124, 245)			
	SMA	Smooth muscle actin			(78, 121)	(22, 25, 121) (117)	(24, 25)		
	ABCG2	ABCG2			(97, 103) (108)	(103)			
	Enriched in adipogenic ASCs or committed preadipocytes	CD105	Endoglin; SH2	(72, 81, 92, 111, 119, 159, 172, 252)	(116)	(103, 107, 108, 159, 163, 244)	(21, 81, 86, 92, 103, 105, 111, 130, 147, 152, 170, 172, 245) (49)	(24, 161, 189)	
CD140a		PDGFR-α			(108)	(22)	(196)		
CD24		BA-1 (binds P-selectin)			(189) (may be very low % of total)		(189)		
Enriched in adipogenic ASCs or committed	CD62L	L-selectin; LECAM-1	(72)		(108)				Different between BM MSCs and SVCs or ASCs (but some inconsistent reports)
	CD104	β4-integrin	(72)			(81)			
	CD106	VCAM-1	(72, 81, 172)		(108, 244)	172 (81, 245)			
	CD49d	α4-integrin; VLA-4	(172) (72, 81)		(108)	(81, 170, 172)			
	Stro-1		(81, 254)			(21, 81, 88) (86, 147)			
Enriched in adipogenic ASCs or committed	CD29	β1-integrin	(72, 81, 92, 172, 252)		(103, 108, 189, 244)	(81, 86, 92, 96, 103, 120, 152, 170, 172)	(189)		
	CD140b	PDGFR-β				(22, 121)	(24)		
	Sca-1	Ly-6A.2	(252)		(104, 135, 158)	(98, 120)	(24, 189)		
	CD9	p24; MRP-1	(72)			(86)			
	CD10	MME; neprilysin	(159, 172)		(47, 106)	(22, 47, 86, 96, 170, 172)		(106)	
	CD13	Aminopeptidase N; APN	(159, 172)		(47, 103, 106, 109, 159)	(22, 47, 81, 86, 96, 103, 109, 145, 147, 152, 170, 172)		(106)	

<i>CD36</i>	CD36; FAT; GPIV			(106)		(106)	No differences across all cell types
<i>CD44</i>	CD44; H-CAM; Pgp-1	(72, 81, 92, 159, 172, 252)		(47, 103, 159, 163, 244)	(21, 47, 81, 86, 92, 96, 98, 103, 120, 145, 147, 152, 170, 172)		
<i>CD49a</i>	$\alpha$ 1-integrin; VLA-1	(72)		(103)	(103, 170)		
<i>CD49b</i>	$\alpha$ 2-integrin; VLA-2	(72)		(108)	(147)		
<i>CD49e</i>	$\alpha$ 5-integrin; VLA-5	(72)		(108)	(86, 96)		
<i>CD51</i>	$\alpha$ V-integrin (vitronectin receptor)	(72)		(108)			
<i>CD54</i>	ICAM-1	(72)		(163)	(86, 245)		
<i>CD55</i>	DAF			(106)	(86, 111)	(106)	
<i>CD59</i>	Protectin	(172)		(106)	(86, 96, 170, 172)	(106)	
<i>CD61</i>	$\beta$ 3-integrin	(72)		(108)			
<i>CD63</i>	CD63; Tspan30			(103)	(103)		
<i>CD65</i>	VIM-2			(106)		(106)	
<i>CD71</i>	TFRC (transferrin receptor)	(72, 81, 172)			(81, 172)		
<i>CD90</i>	(Thy-1)	(72, 81, 92, 111, 159, 172)	(116)	(47, 49, 103, 107, 108, 159, 163, 244)	(21, 22, 47, 81, 92, 96, 103, 105, 111, 124, 130, 147, 163, 170, 172, 245)	(163)	
<i>CD120a</i>	TNFR-I	(72, 172)			(172)	(253)	
<i>CD124</i>	IL-4R	(72, 172)			(172)		
<i>CD271</i>	L-NGFR			(118)	(118)		
<i>3G5</i>				(21)	(21)		
<i>HLA-ABC</i>		(159)		(108, 109, 159)	(86, 96, 109, 145, 245)		
<i>NG2</i>	chondroitin sulfate proteoglycan				(22, 121)	(24)	
<i>CD3</i>	T3			(47)		(106)	
<i>CD4</i>	MHC class II co-receptor: T4	(72)		(106, 108)		(106)	
<i>CD5</i>	CD5; Ly-1			(106)		(106)	
<i>CD8a</i>	MHC I co-receptor: T8			(106, 108)		(106)	
<i>CD11b</i>	Integrin $\alpha$ M; Mac-1	(172)	(116)	(108)	(86, 96, 98, 172)	(24)	
<i>CD11c</i>	Integrin $\alpha$ X; p150; CR4			(108)	(86)		
<i>CD18</i>	$\beta$ 2-integrin	(72)		(108)	(86)		
<i>CD19</i>	B4		(116)	(106)		(106)	
<i>CD20</i>	Ms4a1; Ly-44			(106)		(106)	
<i>CD38</i>	T10; cyclic ADP ribose hydrolase			(106)		(106)	
<i>CD48</i>	Blast-1	(172)			(172)		
<i>CD50</i>	ICAM-3	(72)			(86)		
<i>CD56</i>	NCAM	(119)			(81, 86, 145)		
<i>CD62E</i>	E-selectin; ELAM-1	(72)			(81, 86)		
<i>CD62P</i>	P-selectin; PADGEM	(72)		(108)			
<i>CD135</i>	Flt3/Fli2	(172)			(172)		
<i>HLA-DR</i>		(111, 159)	(116)	(108, 159)	(86, 92, 96, 111, 145, 152, 245)		
<i>CD2</i>	CD58 ligand; LFA-2			(47)			
<i>CD49c</i>	$\alpha$ 3-integrin; VLA-3	(72)					
<i>CD58</i>	LFA-3	(72)					
<i>CD102</i>	ICAM-2	(72)					
<i>CD138</i>	Syndecan-1			(108)			
<i>vimentin</i>	Vim				(47)		
<i>CD184</i>	CXCR4				(145)		
<i>CD243</i>	MDR-1; p170; P-gp			(108)			
<i>Fli-1</i>	Fli-1				(120, 147)		
<i>Ter-119</i>	Ter-119					(24)	
<i>CD16</i>	Fc gamma RIIIA				(81)		
<i>CD25</i>	IL-2R	(72)					
<i>CD41a</i>	gpIIb			(108)			
<i>CD49f</i>	$\alpha$ 6-integrin; VLA-6			(108)			
<i>CD79</i>	Component of BCR		(116)				

**Table S1. Surface marker expression in BM MSCs, SVCs, ASCs, committed preadipocytes and mature adipocytes.** Studies reporting positive expression are shown in red; those reporting negative expression are shown in green; and those reporting mixed results are shown in amber. Studies using cells isolated from mice or rats are shown underlined; all other studies used cells isolated from human tissues. Markers are grouped into common expression patterns, as indicated in the right hand column. Positive or negative expression of some markers is distinctive of more adipogenic ASCs, or of committed preadipocytes, as indicated on the left hand side. In some studies it is not clear whether the 'ASCs' studied are SVC subpopulations or whole, unsorted SVCs; however, we have tried to distinguish between these two cell populations for each study cited. It should also be noted that much more is likely known about surface marker expression in mature adipocytes; however, we have not included such studies here as this is beyond the scope of the present review. ISCT, International Society for Cellular Therapy.